Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
15.1.2020 14:00:00 EET | Business Wire | Press release
Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.
“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr. David Baram, President & CEO, Emendo Biotherapeutics. “We are grateful for such strong support from so many high-quality investors and strategic partners including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”
Emendo Biotherapeutics is pioneering OMNI, a next-generation allele-specific gene editing platform that uses synthetic biology to expand what is possible in genome-editing. In 2019, Emendo granted an option to Takeda to use the OMNI nuclease gene editing program for two research and development targets. Emendo received an undisclosed investment from Takeda Ventures that was converted in the Series B.
Emendo’s OMNI technology enables precision gene editing while maintaining high efficiencies, uniquely addressing dominant indications such as Severe Congenital Neutropenia (SCN), caused by mutations in the neutrophil elastase gene ELANE. Dominant indications represent the vast majority of genetic diseases which until now have been untreatable.
About AnGes
AnGes is a Tokyo and Osaka, Japan-based biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide molecules. AnGes’ lead product HGF plasmid, which received conditional approval in Japan in 2019, is a DNA plasmid which encodes the human Hepatocyte Growth Factor (HGF) gene, an angiogenic (new blood vessel growth) factor for critical limb ischemia (CLI). The company is also developing NF-kB Decoy oligonucleotide for the treatment of inflammatory diseases. For more information please visit www.anges.co.jp.
About Emendo
Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline of clinical programs and extensive intellectual property portfolio. For more information please visit us at www.emendobio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005379/en/
Contact information
Julie Amar
info@emendobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo
Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance and seamless integration into modern smart building, retail and industrial environments. Android 16 enables connected devices to communicate more inte
Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 10:00:00 EEST | Press release
Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo
Queue-it Announces Majority Investment from THL Partners18.8.2026 10:00:00 EEST | Press release
Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations & Data, which includes software companies that help organizations operate, secure, and optimize increasingly complex digita
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom